T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (20)	8/22/1998 2:01:00 PM
From: John Metcalf	Read Replies (1) of 1073

re: making suggestions: I'm one of those investors who has avoided suicide watch this year by holding some late-stage companies like SEPR and ADRX. Though I've been quiet about it, I have some early ones like SIBI also. "Quality company on sale" could encompass a couple approaches to an attractive risk/reward ratio. For example, BCHE gets a favorable rating from low risk, at the expense of lower reward potential. Lamivudine for Hep B is coming to market. Unfortunately, the first approval was ignored because it happened in depressed Philippines. As a profitable entity, BCHE will be a survivor, with rights to its own discoveries and those of Clinichem. Earlier stage companies with capital have acceptable risk (to me) if they can survive without having to go into a bear market for funds or negotiate partnerships from a position of weakness. There are many reasonable investments in potential ten-bagger land: MLNM, VRTX, GILD, CEGE, SEPR -- a long list of these in second and even third tier. Vertex is on this list because it has money. I don't see sufficient reasons to believe in its eventual success.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next